The following article features coverage from the American Association for Cancer Research (AACR) 2018 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

A nanoparticle-based tumor cell lysate vaccine may be effective for slowing cancer growth, according to research being presented at the 2018 American Association for Cancer Research Annual Meeting in Chicago, Illinois.1

Synthetic peptide–based vaccines have shown limited efficacy in cancer overall, as they are not available for all tumor types and are not always immunogenic. Whole tumor cell lysate, another antigen source, may provide a promising alternative.

For this murine model, researchers assessed the efficacy of an imidazaquinoline-based toll-like receptor 7/8 agonist encapsulated in nanoparticles, termed “522,” as an adjuvant anticancer vaccine. The vaccine was combined with whole tumor cell lysate derived from bladder cancer cells. Five doses were administered and the results were compared with those who received controls.

Antigen-specific T cells increased in frequency in vaccinated mice. While at day 30 the tumor volume in controls reached an approximate average size of 1000 mm3, vaccinated mice had an approximate average tumor size of 122 mm3.

The authors concluded that “CD8 T cells generated by […] vaccination appeared to be effective in killing tumors in both prophylactic and therapeutic tumor models. These results suggest that 522 [nanoparticles] are effective vaccine adjuvants capable of improving the outcome of cancer immunotherapy.”

Read more of Cancer Therapy Advisor‘s coverage of the American Association for Cancer Research (AACR) 2018 meeting by visiting the conference page.

Reference

  1. Kim H, Larson P, Kucaba TA, et al. Nanoparticle-based tumor cell lysate vaccine for cancer immunotherapy. Oral presentation at: 2018 American Association for Cancer Research Annual Meeting; April 14-18, 2018; Chicago, IL.